TAK vs NVS

For growth investors, Takeda Pharmaceutical Company Limited (TAK) is the stronger pick with 7.

5% revenue growth year-over-year, versus 6. 0% for Novartis AG (NVS). Novartis AG (NVS) offers the better valuation at 20. 2x trailing P/E (16. 6x forward), making it the more compelling value choice. Analysts rate Takeda Pharmaceutical Company Limited (TAK) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Novartis AG (NVS) is the cheapest at 20.

2x versus Takeda Pharmaceutical Company Limited at 77. 4x. On forward P/E, Takeda Pharmaceutical Company Limited is actually cheaper at 0. 2x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Takeda Pharmaceutical Company Limited wins at 0. 01x versus Novartis AG's 1. 08x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Novartis AG (NVS) delivered a total return of +94.

4%, compared to +17. 6% for Takeda Pharmaceutical Company Limited (TAK). Over 10 years, the gap is even starker: NVS returned +178. 5% versus TAK's -1. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Takeda Pharmaceutical Company Limited (TAK) is the lower-risk stock at 0.

33β versus Novartis AG's 0. 42β — meaning NVS is approximately 30% more volatile than TAK relative to the S&P 500. On balance sheet safety, Takeda Pharmaceutical Company Limited (TAK) carries a lower debt/equity ratio of 65% versus 80% for Novartis AG — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Takeda Pharmaceutical Company Limited (TAK) is pulling ahead at 7.

5% versus 6. 0% for Novartis AG (NVS). On earnings-per-share growth, the picture is similar: Novartis AG grew EPS 22. 5% year-over-year, compared to -26. 2% for Takeda Pharmaceutical Company Limited. Over a 3-year CAGR, TAK leads at 8. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Novartis AG (NVS) is the more profitable company, earning 25.

6% net margin versus 2. 4% for Takeda Pharmaceutical Company Limited — meaning it keeps 25. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVS leads at 31. 2% versus 7. 5% for TAK. At the gross margin level — before operating expenses — NVS leads at 75. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Takeda Pharmaceutical Company Limited (TAK) is the more undervalued stock at a PEG of 0. 01x versus Novartis AG's 1. 08x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Takeda Pharmaceutical Company Limited (TAK) trades at 0. 2x forward P/E versus 16. 6x for Novartis AG — 16. 4x cheaper on a one-year earnings basis.

All stocks in this comparison pay dividends.

Takeda Pharmaceutical Company Limited (TAK) offers the highest yield at 3. 6%, versus 2. 8% for Novartis AG (NVS).

For long-horizon retirement investors, Novartis AG (NVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

42), 2. 8% yield, +178. 5% 10Y return). Both have compounded well over 10 years (NVS: +178. 5%, TAK: -1. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: TAK is a mid-cap income-oriented stock; NVS is a large-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.